Eurocine Vaccines has completed dosing of its quadrivalent influenza vaccine candidate, Immunose™ FLU, in the second clinical study

This week, dosing was completed according to plan in the second clinical study with Immunose™ FLU, developed with the aim to become a modern and effective nasal influenza vaccine.

- In the perspective of this year’s severe influenza outburst we are pleased to have chosen the broader quadrivalent, rather than trivalent, vaccine for our product candidate, says Dr. Anna-Karin Maltais, Chief Scientific Officer.

-The elderly always suffer most from influenza disease and we believe that we can offer a better and more convenient vaccine in this segment. This, without loosing sight of our vision, to offer the first nasal influenza vaccine for children younger than 2 years, adds Hans Arwidsson, CEO of Eurocine Vaccines.

The strategy behind this present study, and its design, was presented in a previous news release dated February 7th, 2018 and can be read at;

The progress of the study can also be followed at;
Results are expected second half of 2018.

Hans Arwidsson, Ph.D., MBA

CEO of Eurocine Vaccines AB

+46 70 634 0171

Eurocine Vaccines is using its clinically validated technology Endocine™ to develop patent protected nasal vaccines. Endocine™, based on endogenous components, brings advantages such as creation of both mucosal and systemic immunity, as well as needle-free and convenient nasal vaccination.

The company´s first product candidate, the nasal quadrivalent influenza vaccine Immunose™ FLU, is currently in clinical phase I/II development, targeted to become the first approved nasal influenza vaccine for children under the age of 2 years. Within the market for influenza vaccines, children is the fastest growing segment. This is due to the recommendation by the WHO to vaccinate children against influenza.

A clinical study conducted with Immunose™ FLU in young adults in the season 2016/2017 showed good safety and immune responses in both nasal mucosa and in serum, which constitutes a good foundation for further development. The next clinical study takes place during the present influenza season, 2017/2018, and includes elderly subjects to generate necessary safety data. Concurrently, the elderly population will be evaluated as an additional business opportunity.

Eurocine Vaccines, EUCI, is traded at Aktietorget, XSAT.

About Us

Eurocine Vaccines is a publicly listed, clinical-stage company developing nasal vaccines that meet important medical needs. The vaccines are developed up to proof of concept (clinical phase I/II) and licensed to partners for further development and commercialization. The company's proprietary vaccine adjuvant technologies, which are a key element of the nasal vaccines, are also offered to license partners for development in various indications. Present focus is on partnering the nasal influenza vaccine program, Immunose™ FLU, which has shown proof of concept in a clinical study, and on preclinical development of a nasal vaccine against bacterial pneumonia.


Documents & Links